Overexpression of indoleamine 2, 3-dioxygenase contributes to the repair of human airway epithelial cells inhibited by dexamethasone via affecting the MAPK/ERK signaling pathway

SHANSHAN JIA¹, PIN GUO², XIANGJIN GE¹, HUANHUAN WU³, JUNHUA LU¹ and XIAOFANG FAN⁴

¹Department of Respiration, Hengdian Wenrong’s Hospital, Dongyang, Zhejiang 322118; ²Department of Urology, Dong Yang Red Cross Hospital; ³Department of Respiration, Dongyang People's Hospital, Jinhua, Zhejiang 322100; ⁴Cor Pulmonale Research Laboratory, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China

Received October 4, 2017; Accepted April 30, 2018

DOI: 10.3892/etm.2018.6163

Abstract. Indoleamine 2, 3-dioxygenase (IDO) catalyzes the degradation of tryptophan, which serves a key role in immune suppression via regulating the production of several metabolites. The present study aimed to explore the effects and mechanisms of IDO in the repair of human airway epithelium suppressed by dexamethasone (DEX). Cell viability, proliferation and migration were evaluated using a Cell Counting Kit-8 (CCK-8), 5(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling, and wound-healing assay, respectively. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blot analysis and ELISA were performed to assess the levels of IDO, the mitogen-activated protein kinase (MAPK)/extracellular regulated kinase (ERK) pathway-related factors and epidermal growth factor (EGF) expression, respectively. The results revealed that overexpression of IDO enhanced the cell viability, and promoted the proliferation and migration of 16HBE cells which repair was inhibited by DEX. Furthermore, it was indicated that overexpression of IDO affected the MAPK/ERK pathway. In conclusion, overexpression of IDO promoted the human airway epithelium repair inhibited by DEX through affecting MAPK/ERK pathway. The present study implied that IDO may be a potential genetic therapeutic agent and supported the utilization of IDO in asthma.

Introduction

Asthma is one of the most common chronic inflammatory airway diseases along with airway epithelial cells injury, which seriously threat to the health of human worldwide (1,2). It is surveyed by World Health Organization (WHO) that there are approximately 235,000,000 people suffering from this disease and causes about 255,000 deaths worldwide annually (3). The proposed therapeutic approach of asthma was the combination of glucocorticoids (GCs) and β₂ receptor agonist. However, the treatment was unable to prevent the recurrence of asthma and the rising of incidence year by year. Hence, to investigate new exact mechanisms and molecular pathways activated in asthma is necessary in developing novel treatment measures and therapeutic drugs in asthma.

Dexamethasone (DEX) represents one of the common GCs drugs, which have been widely used in the treatment of asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis (8,9). GCs play a role in regulating the target gene transcription of glucocorticoid receptors (GR) (10). In the meantime, GCs also possess anti-inflammatory effect through inhibiting the transcription of inflammatory transcription factors, including nuclear factor-kappa B (NF-kB) and activator protein 1 (AP-1) (11). It has been reported that GCs could significantly reduce the proliferation of airway epithelial cells in asthmatic patients and inhibit the airway epithelium repair through restraining the early proliferation and migration of airway epithelial cells (12,13). Nevertheless, the accurate mechanism in the process of airway epithelium repair inhibited by GCs is not clear.

The repair of airway epithelium is achieved primarily through the interaction of epidermal growth factor (EGF) with its epidermal growth factor receptor (EGFR) to activate the mitogen-activated protein kinase (MAPK)/extracellular regulated kinase (ERK) signaling pathway. MAPK/ERK pathway plays a critical role in the process of cell survival, proliferation, migration and differentiation (14). Increasing evidences have shown that the activation of MAPK/ERK pathway
promoted the proliferation, migration and differentiation of peripheral cells around the damage (15,16). Recent studies also have revealed that mitogen-activated protein kinase (Mek1/2) and Erk1/2 specific inhibitors in the MAPK/ERK pathway markedly inhibited the repair of airway epithelium injury (13,17). Furthermore, GCs significantly inhibited the phosphorylation of v-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1) and activation of downstream MAPK/ERK pathway activated by growth factors (18,19). However, Raf-1 phosphorylation is widely considered to be the up-stream signal molecule that plays a key role in the activation of MAPK/ERK pathway. Therefore, we conjectured that GCs inhibited human airway epithelial cells repair might through inhibiting the phosphorylation of Raf-1 and the activation of MAPK/ERK pathway.

Indoleamine 2, 3-dioxygenase (IDO) is a rate-limiting enzyme, which has the function of catalyzing the oxidative decomposition of pyrrole ring in tryptophan molecule (20). IDO widely distributed in the tissues of humans and other mammals (21), including lung, neuroglia, endothelial cells, and visceral epithelial cells (22-25). And the secretion of IDO is impacted by lipopolysaccharide, cytokines, tumor necrosis factor-α (TNF-α), and interferon γ (IFN-γ) (26). It has been demonstrated that the IDO transcriptional induction is the mechanism of neuroendocrine disorders triggered by chronic inflammation (27). Studies also have found that IDO played an essential role in depressive disorder and Alzheimer’s disease (28,29). Nevertheless, as far as we known, the effects and mechanisms of IDO in human airway epithelial cells repair inhibited by DEX have not been reported yet.

Collectively, in this study, we explored the biological roles of IDO on the repair of human airway epithelium inhibited by DEX. Furthermore, mechanisms analysis indicated that IDO positively regulated the expression levels of Raf-1, Mek1/2, and Erk1/2. Together, our study elucidated that IDO promoted the repair of human airway epithelial cells inhibited by DEX through affecting the MAPK/ERK pathway.

Materials and methods

Reagents. All of the products utilized in cell-culture were obtained from Gibco; Thermo Fisher Scientific, Inc., (Waltham, MA, USA). Antibodies were obtained from Abcam (Cambridge, UK). The inhibitor of ERK (PD98059; Item: ML4829; CAS: 167869-21-8) was gained from YuduoBio (Shanghai, China). And the inhibitor of HMGB1 (R, S-Sulforaphane; Item: S6317; CAS: 142825-10-3) was gained from HengfeiBio (Shanghai, China). And the inhibitor of HMGB1 (R, S-Sulforaphane; Item: S6317; CAS: 142825-10-3) was gained from HengfeiBio (Shanghai, China). And the inhibitor of HMGB1 (R, S-Sulforaphane; Item: S6317; CAS: 142825-10-3) was gained from HengfeiBio (Shanghai, China). The inhibitor of ERK (PD98059; Item: ML4829; CAS: 167869-21-8) was gained from YuduoBio (Shanghai, China). And the inhibitor of HMGB1 (R, S-Sulforaphane; Item: S6317; CAS: 142825-10-3) was gained from HengfeiBio (Shanghai, China).

Cell culture. The human lung bronchial epithelial cell line (16HBE) was obtained from ATCC (American Type Culture Collection, Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) mixed with 10% fetal bovine serum (FBS) in a 5% CO₂ atmosphere at 37°C. Afterwards, cells were observed under an inverted microscope for the growth status.

IDO gene recombinant adenovirus transfection. Cultured 16HBE cells were transfectected with objective gene adenovirus (CMV-IDO1-EGFP; FUBIO, Shanghai, China) and sowed into 12-well plates at a density of 1x10⁶ cells per well. After the cells were complete adherence, transfection could be carried out. Before transfection, 500 µl fresh 16HBE cells medium were added to each well to replace the quondam cells. 15 µl adenovirus were added to the wells, and then cells were cultured in the incubator after shaking (37°C, 5% CO₂, 95% relative humidity). 8 h later, the medium with adenovirus was removed and cells were washed by PBS twice. Fresh medium were added to the cells and cells were then cultured in the incubator (37°C, 5% CO₂, 95% relative humidity). After 30 h, 16HBE cells transfected with IDO gene were harvest.

Western blot analysis. Proteins from 16HBE cells were obtained and bicinchoninic acid assay was performed to detect the protein concentration. After that, equal quantity of proteins (50 µg) were solubilized in 5x sodium dodecyl sulfate (SDS)-sample buffer and separated on the SDS polyacrylamide gels (Thermo Fisher Scientific, Inc.). Separated proteins were then transferred onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). After blocking, the membranes were incubated with anti-IDO (dilution, 1:500; ab55305); anti-p-Raf-1 (dilution, 1:500; ab208449); anti-Raf-1 (dilution, 1:1,000; ab20588); anti-p-Mek1/2 (dilution, 1:1,000; ab194754); anti-Mek1/2 (dilution, 1:1,000; ab215263); anti-p-Erk1/2 (dilution, 1:1,000; ab201015); anti-Erk1/2 (dilution, 1:1,000; ab17942); anti-GAPDH (dilution, 1:1,000, ab8245; all from Abcam) antibodies overnight at 4°C. After that, horseradish peroxidase-conjugated secondary antibodies (bs-0293M; BIOSS, Beijing, China) were added and incubated at room temperature for 1 h. The results of all the assessments were evaluated by enhanced chemiluminescent reagents (EMD Millipore).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. About 5x10⁵/well 16HBE cells were cultured in 6-well plates and treated with control, NC (Adenovirus empty vector; FUBIO, Shanghai, China), DEX (D1756; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), or IDO. And then the total RNA was extracted from 16HBE cells by TRIZol (DP405-02; Tiangen Biotech Co., Ltd., Beijing, China) as suggested by the manufacturers. Afterwards, two microliters of RNA was used for cDNA synthesis with a first strand cDNA kit (Sigma-Aldrich; Merck KGaA) following the specification. RT-qPCR was performed on the SYBR Green Premix Reagent (Takara Bio, Inc., Otsu, Japan) by ABI 7500 Thermocycler (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR cycles were under the following conditions: 10 min pretreatment at 94°C, 95°C for 5 sec, 65°C for 30 sec (35 cycles), 95°C for 15 sec, 60°C for 1 min, 95°C for 15 sec, a final extension at 72°C for 10 min and held at 4°C. The primers were designed by Shanghai Sangong Pharmaceutical Co., Ltd., (Shanghai, China) and were as followed: IDO, forward: 5’-ATG CAGACTGTGTCTTGCGCA-3’ and reverse: 5’-GCCGCTTATGCAAAGAGACCT-3’; Raf-1 forward: 5’-CGACCACTTGCTTCTGCGCA-3’ and reverse: 5’-GCCGCTTATGCAAAGAGACCT-3’; Mek1 forward: 5’-GGCTACTGAGTTCGCAAGATGCT-3’ and reverse: 5’-CCGCTACTGAGTTCGCAAGATGCT-3’; Erk1/2 forward: 5’-TTTATGTTGCTATGCAAGCA-3’ and reverse: 5’-GGACTGATGATGATGATGATG-3’; GAPDH forward: 5’-GCCAGCCGTTAGGAAA-3’ and reverse: 5’-GCCGCCC.
AATCGACCAAATC-3’ (product: 168 bp). And GAPDH was used as the control for the input RNA level.

Cell viability analysis. Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology, Shanghai, China) assay was performed to evaluate the cell viability. About 6x10⁴ cells/ml of 16HBE cells in the logarithmic phase were sowed into the wells of 96-well plates and cultured in the incubator (37˚C, 5% CO₂) for 12 h. Cells were treated with control, NC, DEX, or IDO, respectively. Cells were then maintained in the incubator (37˚C, 5% CO₂) for 12 h. The absorbance at 450 nm was read by enzyme labeling instrument. Cell viability was evaluated by the percentage of cell survival compared with control.

ELISA. Cultured 16HBE cells were treated with control, NC, DEX, or IDO, respectively. Then wells were sealed up by adhesive tape, and incubated for 90 min at 37˚C. 100 µl biotinylated antibody fluids were added to each well, except for the blank wells. Then wells were sealed up by adhesive tape and maintained at 37˚C for 60 min. Enzyme solution was prepared in advance for 30 min, and placed away from the light at room temperature. After washing, 100 µl enzyme solutions were added to each well. Wells were sealed with adhesive tape and maintained at 37˚C for 30 min. After washing, chromogenic substrate was added to each well, except for the blank wells. Then plates were incubated in the dark at 37˚C for 10-15 min. The stop solution was added to each well, and mixed in 10 min immediately. Finally, the OD450 value was measured.

5(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling. Cultured 16HBE cells were suspended in PBS at a final concentration of 1x10⁶ cells/ml. After that, 5 µM CFSE (Thermo Fisher Scientific, Inc.) was added into the cells. After maintaining at 37˚C for 10 min, cells were treated with 10 volumes of ice-cold culture medium (10% FBS). Then cells were maintained on ice for 5 min. After centrifugation, cells were washed by medium twice and subsequently seeded in 24-well plates (about 1x10⁴ cells per well). Afterwards, flow cytometry was performed to evaluate the CFSE fluorescence intensity.

Wound-healing assay. Cultured 16HBE cells were seeded in 24-well plates (about 1x10⁵ cells per well) and treated with control, NC, DEX, or IDO, respectively. Cells were incubated for 15 days until the fusion rate to 100%. Horizontal lines were drawn by a 10 µl pipette tip at the bottom of the 24-well plates through the culture hole. Cells were washed by Hanks liquor three times to remove the crossed cells. The serum-free medium (1% B27, 2 mmol/l glutamine, and 10 µl/ml penicillin-streptomycin) was added to cells. Cells were maintained in the incubator (37˚C, 5% CO₂) and pictures were taken using a fluorescence microscope after culturing for 24 or 0 h and 24 h, respectively.

Statistical analysis. Our data were expressed as mean ± SEM of at least three independent experiments. Statistical analysis was performed using IBM SPSS statistical software (v19; IBM Corp., Armonk, NY, USA). The differences in characteristics among the experimental groups in western blot analysis, RT-qPCR analysis, cell viability analysis, ELISA, CFSE labeling, and wound-healing assay were examined by one-way ANOVA and Tukey’s test. P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of IDO mRNA and IDO protein in 16HBE cells. We detected the effect of IDO on the expression of IDO mRNA and IDO protein in 16HBE cells. We found that IDO significantly enhanced mRNA levels of IDO after treatment compared with the untreated control cells and treated with NC cells (P<0.05; Fig. 1A). According to the western blot results (Fig. 1B), the protein levels of IDO in 16HBE cells treated with IDO were markedly higher than control group and NC group (P<0.05). Thus, it was confirmed that the expression levels of IDO were enhanced by IDO gene in airway epithelial cells in vitro.

Overexpression of IDO enhanced the cell viability of 16HBE cells inhibited by DEX. The results of CCK-8 assays showed that the cell viability of 16HBE cells treated with DEX and NC+DEX were significantly lower than untreated control cells, while a sharp increase was observed in 16HBE cells treated with IDO+DEX (P<0.05; Fig. 1C). According to the processing time, we found that the trends of cell viability with 48 h treatment were more obvious than those with 12 and 24 h. These results indicated that overexpression of IDO enhanced the cell viability of 16HBE cells inhibited by DEX.

Overexpression of IDO promoted proliferation and migration of 16HBE cells inhibited by DEX. As CFSE labeling results shown in Fig. 2, the cell proliferation rates of 16HBE cells treated with DEX were markedly lower than control (P<0.05). However, after treating with IDO, the cell proliferation rate was distinctly increased (P<0.05; Fig. 2), which indicated that overexpression of IDO enhanced the cell proliferation capacity of 16HBE cells inhibited by DEX. Moreover, we found that DEX obviously restrained the 16HBE cells migration, while IDO evidently remitted the suppression and promoted the cell migration, as assessed by wound-healing assay (P<0.05; Fig. 3). Furthermore, we also evaluated the expression levels of related proliferation- and migration-associated factors in 16 HBE cells in each group. We found that the EGF expression in five treatment groups had no significant differences, which indicated that DEX and overexpression of IDO had little effect on the EGF expression (Fig. 4A). The mRNA expression levels of Ki67 and high-mobility group box 1 protein (HMGB1) were significantly reduced by treating with DEX, while sharp increases were observed in IDO+DEX groups (P<0.05; Fig. 4B). These results revealed that DEX significantly down-regulated the expression levels of Ki67 and HMGB1, while IDO markedly up-regulated the Ki67 and HMGB1 expression. Therefore, we could draw the conclusion that overexpression of IDO promoted the proliferation and migration abilities of 16HBE cells inhibited by DEX through regulating the expression levels of Ki67 and HMGB1, respectively.

Overexpression of IDO affected the MAPK/ERK pathway. Furthermore, we detected the expression levels of p-Raf-1,
Raf-1, p-Mek1/2, Mek1/2, p-Erk1/2, and Erk1/2 in 16 HBE cells from each group. Western blot results indicated that the expression levels of p-Raf-1 in 16HBE cells treated with DEX were significantly lower than control; in the meantime, distinct increases of p-Raf-1 levels were observed in the 16HBE cells treated with IDO (P<0.05; Fig. 5A). However, the expression levels of Raf-1 in five groups had no significant difference (Fig. 5A). The expression levels of p-Mek1/2 in DEX groups were markedly lower than control, while the p-Mek1/2 levels were evidently increased by treating with IDO (P<0.05; Fig. 5B). Nevertheless, the expression levels of Mek1/2 in five groups had no significant difference (Fig. 5B). And compared with control group, the expression levels of p-Erk1/2 were markedly reduced by DEX, while the p-Erk1/2 expression in 16HBE cells treated with IDO was significantly enhanced (P<0.05; Fig. 5C). Besides, the expression levels of Erk1/2 in all of the groups had no significant difference (Fig. 5C). Therefore, it was affirmed that overexpression of IDO affected the MAPK/ERK pathway in the repair of human airway epithelial cells inhibited by DEX.

In order to further verify the impact of ERK and HMGB1 on the cell proliferation and migration modulated by overexpression of IDO, the ERK inhibitor (PD98059) and HMGB1 inhibitor (R, S-Sulforaphane) were used in our current study. According to the CFSE labeling results, we found that after inhibiting the expression of ERK, the cell proliferation of 16HBE cells from each treatment group was evidently reduced (P<0.05; Fig. 6A). The wound-healing assay data also indicated that inhibition of ERK obviously lessened the migration ability of 16HBE cells (P<0.05; Fig. 6B). Moreover, it was proved that the migration ability of 16HBE cells was distinctly decreased by treating with HMGB1 inhibitor (P<0.05; Fig. 6C). Hence, we could testify the conclusion above that overexpression of IDO modulated the cell proliferation and migration of 16HBE cells through regulating the expression levels of ERK and HMGB1.
Asthma is mainly characterized by chronic airway inflammation, and airway epithelial injury represents a critical pathological basis of asthma. The dysfunctional epithelium in asthmatic patients reveals abnormal structures, biochemical and immune functions, which together lead to barriers of the airway epithelium defense. It has been proved that the desquamation parts of airway epithelium had significant structural changes (30). Ovalbumin (OVA) sensitization is a common method used for establishing asthma models, which was typical of airway epithelium abscission together with cell apoptosis and could not be inhibited by regular hormone therapy (6). Studies have demonstrated that the related proteins maintaining integrity of airway epithelial cells in asthmatic patients were changed, including tight junction protein, adhesion junction protein, E-cadherin, basal cell marker, and cytokeratin-5 (31-33). In the meantime, abnormal release of growth factors and production of extracellular matrix from airway epithelial cells in asthmatic patients were observed (34,35). These reasons above are important factors that affect the repair of airway epithelial cells.

IDO is known as an immunosuppressive enzyme, which plays an important role in inducing autoimmune diseases, maternal-fetal immune tolerance, tumor escape, and transplantation immune tolerance (36). Previous studies have proved that IDO was expressed by many tumors as well as by infiltrating leucocytes presented within the tumor microenvironment (37-39). It has been demonstrated recently that airway epithelial cells produced IDO, and IDO contributed to the epithelial cells-mediated inhibition of T cell activation (40). Therefore, in the present study, we investigated the mRNA and protein expression levels of IDO in human airway epithelial cells treated with IDO. It was suggested that compared with...
NC, IDO significantly up-regulated the expression of IDO in 16HBE cells. There is evidence that long-term inhalation of GCs might give rise to lung damage in asthmatic patients (41), and DEX has been proved that inhibited the repair of airway epithelium (42). However, the effects of IDO on the cell viability and proliferation capacity of airway epithelial cells are not clear. In our study, we found that the 16HBE cell proliferation capacity suppressed by DEX was obviously enhanced by overexpression of IDO. Hence, to the best of our knowledge, we confirmed that IDO expression affected the 16HBE cells growth and proliferation. According to the previous studies, the expression levels of EGF in human airway epithelial cells could be regulated by retinol and all transretinoic acid (43,44). However, our results revealed that the EGF expression in 16HBE cells was not affected by IDO. Additionally, overexpression of IDO markedly enhanced the expression level of Ki67 in 16 HBE cells. All together, it was demonstrated that overexpression of IDO strengthened the cell proliferation capacity of airway epithelial cells suppressed by DEX through regulating the expression level of Ki67. Besides, we also found that overexpression of IDO significantly enhanced the migration ability of 16HBE cells inhibited by DEX. The abilities of migration and wound repair of airway epithelial cells were demonstrated that could be strengthened by ATP-mediated activation of

Figure 5. Overexpression of IDO affected the MAPK/ERK pathway. Western blot assay was performed on the protein expression levels of (A) p-Raf-1, Raf-1, p-Mek1/2 Mek1/2 (B) p-Erk1/2 and (C) Erk1/2 in 16HBE cells treated with control, NC, DEX, NC+DEX, and IDO+DEX. *P<0.05, **P<0.01 vs. control, ^P<0.05, ^^P<0.01 vs. NC. IDO, indoleamine 2, 3-dioxygenase; MAPK, mitogen-activated protein kinase; ERK, extracellular regulated kinase; p-Raf-1, phosphorylated-v-raf-1 murine leukemia viral oncogene homolog 1; p-Mek1/2, phosphorylated-mitogen-activated protein kinase; NC, negative control; DEX, dexamethasone.
dual oxidase 1 (45). Nevertheless, the effective role of IDO played in promoting airway epithelial cell migration was first studied in our research. We also investigated the exact mechanisms of IDO affecting the airway epithelial cell migration. On the basis of reported literature (46), we chose HMGB1 as the object of study. It was indicated that overexpression of IDO significantly enhanced the mRNA expression level of HMGB1 in 16HBE cells suppressed by DEX. These results suggested that overexpression of IDO enhanced the migration ability of 16HBE cells inhibited by DEX via up-regulating the expression level of HMGB1. It has been demonstrated that the expression of MAPK/ERK pathway in human airway epithelial cells could be impacted by 15-Lipoxigenase 1 interacts with phosphatidylethanolamine-binding protein. Nevertheless, the relationship between IDO and the regulation of MAPK/ERK pathway in human airway epithelial cells is not clear. Therefore, we assessed the expression levels of phosphorylated Raf-1, Mek1/2, and Erk1/2 in 16HBE cells treated with DEX and IDO. The results showed that overexpression of IDO enhanced the phosphorylation of Raf-1, Mek1/2, and Erk1/2 in 16HBE cells suppressed by DEX. These consequences indicated that overexpression of IDO might be an important regulator in the control of MAPK/ERK pathway in human airway epithelium.

In our study, we proved that overexpression of IDO contributed to the repair of 16HBE human airway epithelial cells inhibited by DEX via affecting the MAPK/ERK pathway. However, there also had some limitations in our works. We have only assessed one human lung bronchial epithelial cell line. However, the effectiveness of IDO in promoting airway epithelial cell migration was first studied in our research. We also investigated the exact mechanisms of IDO affecting the airway epithelial cell migration. On the basis of reported literature (46), we chose HMGB1 as the object of study. It was indicated that overexpression of IDO significantly enhanced the mRNA expression level of HMGB1 in 16HBE cells suppressed by DEX. These results suggested that overexpression of IDO enhanced the migration ability of 16HBE cells inhibited by DEX via up-regulating the expression level of HMGB1. It has been demonstrated that the expression of MAPK/ERK pathway in human airway epithelial cells could be impacted by 15-Lipoxigenase 1 interacts with phosphatidylethanolamine-binding protein. Nevertheless, the relationship between IDO and the regulation of MAPK/ERK pathway in human airway epithelial cells is not clear. Therefore, we assessed the expression levels of phosphorylated Raf-1, Mek1/2, and Erk1/2 in 16HBE cells treated with DEX and IDO. The results showed that overexpression of IDO enhanced the phosphorylation of Raf-1, Mek1/2, and Erk1/2 in 16HBE cells suppressed by DEX. These consequences indicated that overexpression of IDO might be an important regulator in the control of MAPK/ERK pathway in human airway epithelium. However, there also had some limitations in our works. We have only assessed one human lung bronchial epithelial cell line. Nevertheless, the effectiveness of IDO in promoting airway epithelial cell migration was first studied in our research. We also investigated the exact mechanisms of IDO affecting the airway epithelial cell migration. On the basis of reported literature (46), we chose HMGB1 as the object of study. It was indicated that overexpression of IDO significantly enhanced the mRNA expression level of HMGB1 in 16HBE cells suppressed by DEX. These results suggested that overexpression of IDO enhanced the migration ability of 16HBE cells inhibited by DEX via up-regulating the expression level of HMGB1. It has been demonstrated that the expression of MAPK/ERK pathway in human airway epithelial cells could be impacted by 15-Lipoxigenase 1 interacts with phosphatidylethanolamine-binding protein. Nevertheless, the relationship between IDO and the regulation of MAPK/ERK pathway in human airway epithelial cells is not clear. Therefore, we assessed the expression levels of phosphorylated Raf-1, Mek1/2, and Erk1/2 in 16HBE cells treated with DEX and IDO. The results showed that overexpression of IDO enhanced the phosphorylation of Raf-1, Mek1/2, and Erk1/2 in 16HBE cells suppressed by DEX. These consequences indicated that overexpression of IDO might be an important regulator in the control of MAPK/ERK pathway in human airway epithelium.
line in our investigation, which might have limitations about the current conclusion. Hence, in the future, the in vivo DEX-induced rat models will be further used to investigate the roles and mechanisms of IDO in the therapy of asthma. Moreover, we noted that Akt/mTOR signaling pathway might be involved in mediating the effects of IDO treatment on cell migration and proliferation, which will also be considered in our subsequent research.

In the current study, it is suggested that the overexpression of IDO is conducive to the repair of human airway epithelial cells inhibited by DEX. According to the previous article, functional IDO expression is high in the lung (47). It has been proved that immature dendritic cells expressing IDO inhibit OVA-induced allergic airway inflammation in vivo (48). In addition, another study has confirmed that knocking down IDO activity markedly decreased the ability of human airway epithelial cells (40). However, the IDO-only treated control group has not been designed in this study. Of course, the addition of the IDO-only treated control group will make the experiment more convincing.

Studies have reported that the asthmatic airway epithelium revealed injury and shedding after GCs treatment. Our results found that overexpression of IDO enhanced the proliferation and migration of 16HBE cells inhibited by DEX. Besides, IDO overexpressing up-regulated MAPK/ERK pathway in 16HBE cells treated with DEX. Altogether, our findings first suggested that overexpression of IDO contributed to the repair of human airway epithelium suppressed by DEX through up-regulating MAPK/ERK pathway. Our work provided an understanding that IDO might be a potential genetic therapeutic agent and supported the utilization of IDO in asthma.

In conclusion, the inhibition of epithelial injury repair by DEX was ameliorated in part by the overexpression of IDO, which enhanced airway epithelial cell viability, proliferation, and migration through up-regulating the MAPK/ERK pathway.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
SJ wrote the article. SJ, PG and XG performed the experiments. SJ and PG designed the study. SJ, HW, JL and XF performed data analysis. HW, JL and XF contributed to manuscript revisions and all authors reviewed the manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Nakawat MO, Hawkins C and Barbandi F: Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome. J Am Board Fam Med 26: 470–477, 2013.
2. Papayannos A, Zaragoulidh P, Porpodis K, Spyridatos D, Kiounis I, Pitsiou G, Patakà A, Tsakiris K, Arikas S, Mpakas A, et al: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): Current literature review. J Thorac Dis 6 (Suppl 1): S146-S151, 2014.
3. Zalewska M, Furmańczyk K, Jaworski S, Niemiro W and Samoliński B: The prevalence of asthma and declared asthma in Poland on the basis of ECAP survey using correspondence analysis. Comup Math Methods Med 2013: 597845, 2013.
4. Tam A, Wadsworth S, Dorscheid D, Man SF and Sin DD: The airway epithelium: More than just a structural barrier. Ther Adv Respir Dis 5: 255-273, 2011.
5. Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, Panizzolo C, Zanin ME, Zuin R, Maestrelli P, Fabbri LM and Saetta M: Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med 174: 975-981, 2006.
6. Dorscheid DR, Wojcik KR, Sun S, Marroquin B and White SR: Apoptosis of airway epithelial cells induced by corticosteroids. Am J Respir Crit Care Med 164: 1939-1947, 2001.
7. Holgate ST: The airway epithelium is central to the pathogenesis of asthma. Allergol Int 57: 1-10, 2008.
8. Kardos Z: Treatment of chronic obstructive pulmonary disease with inhaled pharmacotheraphy: Role of corticosteroids. Acta Pharm Hung 82: 33-41, 2012 (In Hungarian).
9. Spangler DL: The role of inhaled corticosteroids in asthma treatment: A health economic perspective. Am J Manag Care 16 (2 Suppl): S33-S39, 2012.
10. De Bosscher K, Vanden Berghe W and Haegeman G: Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: Negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 109: 16-22, 2000.
11. Davies L, Karthikeyan N, Lynch JT, Sial EA, Gkourtas A, Demonoacos C and Krsit-Demonoaclos M: Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function. Mol Endocrinol 22: 1331-1344, 2008.
12. Benayoun L, Letuve S, Drulhle A, Bozcowski J, Dombret MC, Mechechel P, Mégret J, Lesche G, Aubier M and Pretolani M: Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: Relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med 164: 1487-1494, 2001.
13. Wadsworth SJ, Nijmeh HS and Hall JP: Glucocorticoids increase repair potential in a novel in vitro human airway epithelial wounded model. J Clin Immunol 26: 376-387, 2006.
14. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22: 153-183, 2001.
15. Montiel M, Quesada J and Jiménez E: Activation of calcium-dependent kinases and epidermal growth factor receptor regulate muscarinic acetylcholine receptor-mediated MAPK/ERK activation in thyroid epithelial cells. Cell Signal 19: 2138-2146, 2007.
16. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
17. Lind CR, Gray CW, Pearson AG, Cameron RE, O’Carroll SJ, Narayan PJ, Lim J and Dragunow M: The mitogen-activated/extracellular signal-regulated kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells. Neuroscience 141: 1925-1933, 2006.
Biol Psychiatry 33.

Dojčinović E and Frédérick R: Indoleamine 2,3-dioxygenase inhibitors: A patent review (2008-2012). Expert Opin Ther Pat 23: 1367-1381, 2013.

Bai TR and Hackett TL, Warner SM, Stefanowicz D, Shaheen F, Akkaya A, Kicic A, Sutanto EN, Knight DA and Stick SM: Role of indoleamine 2,3-dioxygenase in smoking and tobacco smoke exposure. Toxicol Appl Pharmacol 278: 161-171, 2014.

Rhee TK and Cidlowski JA: Antinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353: 1711-1723, 2005.

Dolůšič E and Frédérick R: Indoleamine 2,3-dioxygenase inhibitors: A patent review (2008-2012). Expert Opin Ther Pat 23: 1367-1381, 2013.

Liu X, Newton RC, Friedman SM and Scherer PA: Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets 9: 938-952, 2009.

Herbert A, Ng H, Jessup W, Kocks M, Cartland S, Thomas SR, Blazer K and Akdis CA: Apoptosis and loss of adhesion of bronchial epithelial cells in asthma. Thorax 24: 176-179, 1969.

Dunnill MS, Massarella GR and Anderson JA: A comparison of the quantitative anatomy of the bronchi in normal subjects, females. In Vivo 28: 633-638, 2014.

Pliatsika P, Boufidou F, Foteli S, Soldatos CR, Nikolaou C and Zoga M, Oulis P, Chatzipanagiotou S, Masdrakis VG, Amyotrophic lateral sclerosis - new mechanisms for old drugs. Mol Med 17: 1711-1723, 2005.

Yeung AW, Terentis AC, King NJ and Thomas SR: Role of indoleamine 2,3-dioxygenase in health and disease. Clin Sci (Lond) 129: 601-672, 2015.

Raf-1. Riccardi C: Glucocorticoid- induced leucine zipper inhibits the Raf-extracellular signal -regulated kinase pathway by binding to Raf-1. Mol Cell Dev Biol 46: 21-27, 2010.

Muller A and Däubener W: Role of high -mobility group box-1 (HMGB1) as a danger signal in inflammatory diseases. J Investig Allergol Clin Immunol 21: 1986-1993, 2011.

Rhein TA, Whitehead M, Prowant JR, Colvin RB and Cutright DA: The proliferative effects of retinoic acid on primary cultures of epithelial cells of children with asthma. Am J Respir Crit Care Med 174: 1711-1723, 2006.

Trautmann A, Kruger K, Akdis M, Muller-Wening D, Akkaya A, Blazer K and Akdis CA: Apatosis and loss of adhesion of bronchial epithelial cells in asthma. Int Arch Allergy Immunol 138: 142-150, 2005.

Hackett TL, Warner SM, Stefanowicz D, Shaheen F, Pechkovsky DV, Murray LA, Argentieri R, Kicic A, Stick SM, Bai TR and Knight DA: Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta. Am J Respir Crit Care Med 180: 122-133, 2009.